Patients’ and Healthcare Professionals’ Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational Survey
Lisa H. Lancaster
Claudia Valenzuela
Wendi Mason
Claus Neurohr
Elena Ripamonti
Klaus-Uwe Kirchgaessler
Vincent Cottin
10.6084/m9.figshare.11871381.v1
https://adisjournals.figshare.com/articles/figure/Patients_and_Healthcare_Professionals_Experiences_of_Idiopathic_Pulmonary_Fibrosis_Treatment_with_the_Pirfenidone_801_mg_Tablet_Formulation_A_Multinational_Survey/11871381
<p>The above summary slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).<br></p>
<p>© The authors, CC-BY-NC 2020. </p><p></p>
2020-03-10 11:13:28
Antifibrotics
Idiopathic pulmonary fibrosis
Pill burden
Pirfenidone
Quality of life
Questionnaire